{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:16:07Z","timestamp":1793103367792,"version":"4.5.0"},"reference-count":58,"publisher":"Open Medical Publishing","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Spinal muscular atrophy (SMA) is a rare, autosomal recessive neuromuscular degenerative disease characterized by loss of spinal cord motor neurons leading to progressive muscle wasting. The most common pathology results from a homozygous disruption in the survival motor neuron 1 (SMN1) gene on chromosome 5q13 via deletion, conversion, or mutation. SMN2 is a near duplicate of SMN1 that can produce full-length SMN mRNA transcripts, but its overall production capability of these mRNA transcripts is lower than that seen in SMN1. This leads to lower levels of functional SMN protein within motor neurons. The FDA approved nusinersen in December 2016 to treat SMA associated with SMN1 gene mutation. It is administered directly to the central nervous system by intrathecal injection. An antisense oligonucleotide (ASO) drug, nusinersen, provides an upcoming and promising treatment option for SMA and represents a novel pharmacological approach with a mechanism of action relevant for other neurodegenerative disorders. Nusinersen begins with four initial loading doses that are followed by three maintenance doses per year. Three major studies (CHERISH, ENDEAR, and NURTURE) have shown to improve motor function in early and late-onset individuals and reduce the chances of ventilator requirements in pre-symptomatic infants. Studies investigating the timing of drug delivery in mouse models of SMA report the best outcomes when drugs are delivered early before any significant motor function is lost. Nusinersen is a novel therapeutic approach with consistent results in all three studies and is proof of the novel concept for treating SMA and other neurodegenerative disorders in the future.<\/jats:p>","DOI":"10.52965\/001c.24934","type":"journal-article","created":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T13:22:45Z","timestamp":1624627365000},"source":"Crossref","is-referenced-by-count":41,"title":["The Antisense Oligonucleotide Nusinersen for Treatment of Spinal Muscular Atrophy"],"prefix":"10.52965","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7436-6206","authenticated-orcid":false,"given":"Amber N.","family":"Edinoff","sequence":"first","affiliation":[{"name":"Louisiana State University Health Science Center Shreveport","department":["Department of Psychiatry and Behavioral Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long H.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Louisiana State University Health Science Center Shreveport","department":["Department of Psychiatry and Behavioral Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira S.","family":"Odisho","sequence":"additional","affiliation":[{"name":"Louisiana State University Health Science Center Shreveport","department":["Department of Psychiatry and Behavioral Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin S.","family":"Maxey","sequence":"additional","affiliation":[{"name":"Louisiana State University Health Science Center Shreveport","department":["School of Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Pruitt","sequence":"additional","affiliation":[{"name":"Louisiana State University Health Science Center Shreveport","department":["School of Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brook","family":"Girma","sequence":"additional","affiliation":[{"name":"Louisiana State University Health Science Center Shreveport","department":["Department of Anesthesiology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyse M.","family":"Cornett","sequence":"additional","affiliation":[{"name":"Louisiana State University Health Science Center Shreveport","department":["Department of Anesthesiology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M.","family":"Kaye","sequence":"additional","affiliation":[{"name":"Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific","department":["Department of Pharmacy Practice"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Kaye","sequence":"additional","affiliation":[{"name":"Louisiana State University Health Science Center Shreveport","department":["Department of Anesthesiology"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"30777","published-online":{"date-parts":[[2021,6,19]]},"reference":[{"issue":"8","key":"ref1","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/archneurol.2011.74","article-title":"Spinal muscular atrophy: A timely review","volume":"68","author":"Stephen J. Kolb","year":"2011","journal-title":"Archives of Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0003-9942","issn-type":"print"},{"issue":"2","key":"ref2","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s13311-014-0314-x","article-title":"The Genetics of Spinal Muscular Atrophy: Progress and Challenges","volume":"12","author":"Michelle A. Farrar","year":"2015","journal-title":"Neurotherapeutics","ISSN":"https:\/\/id.crossref.org\/issn\/1878-7479","issn-type":"print"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.06077-11","article-title":"A Role for SMN Exon 7 Splicing in the Selective Vulnerability of Motor Neurons in Spinal Muscular Atrophy","author":"M. Ruggiu","year":"2012","journal-title":"Molecular and Cellular Biology","ISSN":"https:\/\/id.crossref.org\/issn\/0270-7306","issn-type":"print"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200304128","article-title":"Smn, the spinal muscular atrophy-determining gene product, modulates axon growth and localization of \u03b2-actin mRNA in growth cones of motoneurons","author":"Wilfried Rossoll","year":"2003","journal-title":"Journal of Cell Biology","ISSN":"https:\/\/id.crossref.org\/issn\/0021-9525","issn-type":"print"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1523\/jneurosci.23-16-06627.2003","article-title":"Active transport of the survival motor neuron protein and the role of exon-7 in cytoplasmic localization","author":"Honglai L. Zhang","year":"2003","journal-title":"Journal of Neuroscience","ISSN":"https:\/\/id.crossref.org\/issn\/0270-6474","issn-type":"print"},{"issue":"3","key":"ref6","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.jpeds.2011.08.016","article-title":"Prevalence and risk factors for feeding and swallowing difficulties in spinal muscular atrophy types II and III","volume":"160","author":"Yen Shan Chen","year":"2012","journal-title":"Journal of Pediatrics","ISSN":"https:\/\/id.crossref.org\/issn\/1097-6833","issn-type":"print"},{"issue":"8","key":"ref7","doi-asserted-by":"publisher","first-page":"e437","DOI":"10.1542\/neo.20-8-e437","article-title":"Spinal muscular atrophy: Past, present, and future","volume":"20","author":"Lainie Friedman Ross","year":"2019","journal-title":"NeoReviews","ISSN":"https:\/\/id.crossref.org\/issn\/1526-9906","issn-type":"print"},{"issue":"8","key":"ref8","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1177\/0883073807305788","article-title":"Consensus statement for standard of care in spinal muscular atrophy","volume":"22","author":"Ching H. Wang","year":"2007","journal-title":"Journal of Child Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0883-0738","issn-type":"print"},{"issue":"3","key":"ref9","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/ana.24864","article-title":"Emerging therapies and challenges in spinal muscular atrophy","volume":"81","author":"Michelle A. Farrar","year":"2017","journal-title":"Annals of Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/1531-8249","issn-type":"print"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.pediatrneurol.2015.12.015","article-title":"Nutritional status and nutrient intake challenges in children with spinal muscular atrophy","volume":"57","author":"Nilesh M. Mehta","year":"2016","journal-title":"Pediatric Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/1873-5150","issn-type":"print"},{"issue":"4","key":"ref11","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","article-title":"Spinal Muscular Atrophy","volume":"33","author":"Stephen J. Kolb","year":"2015","journal-title":"Neurologic Clinics","ISSN":"https:\/\/id.crossref.org\/issn\/1557-9875","issn-type":"print"},{"issue":"9630","key":"ref12","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","article-title":"Spinal muscular atrophy","volume":"371","author":"Mitchell R. Lunn","year":"2008","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"issue":"11","key":"ref13","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1177\/0883073813503988","article-title":"Nutritional practices at a glance: Spinal muscular atrophy type i nutrition survey findings","volume":"29","author":"Rebecca Hurst Davis","year":"2014","journal-title":"Journal of Child Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/1708-8283","issn-type":"print"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/1471-2474-14-283","article-title":"Natural course of scoliosis in proximal spinal muscular atrophy type II and IIIa: Descriptive clinical study with retrospective data collection of 126 patients","volume":"14","author":"Albert Fujak","year":"2013","journal-title":"BMC Musculoskeletal Disorders","ISSN":"https:\/\/id.crossref.org\/issn\/1471-2474","issn-type":"print"},{"issue":"3","key":"ref15","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.spinee.2014.09.030","article-title":"Postoperative quality of life in patients with progressive neuromuscular scoliosis and their parents","volume":"15","author":"Kyung Soo Suk","year":"2015","journal-title":"Spine Journal","ISSN":"https:\/\/id.crossref.org\/issn\/1878-1632","issn-type":"print"},{"issue":"1","key":"ref16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JND-190424","article-title":"Advances in Treatment of Spinal Muscular Atrophy - New Phenotypes, New Challenges, New Implications for Care","volume":"7","author":"David C. Schorling","year":"2020","journal-title":"Journal of Neuromuscular Diseases","ISSN":"https:\/\/id.crossref.org\/issn\/2214-3602","issn-type":"print"},{"issue":"11","key":"ref17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11910-017-0798-y","article-title":"Treatment Advances in Spinal Muscular Atrophy","volume":"17","author":"Diana Bharucha-Goebel","year":"2017","journal-title":"Current Neurology and Neuroscience Reports","ISSN":"https:\/\/id.crossref.org\/issn\/1534-6293","issn-type":"print"},{"issue":"7","key":"ref18","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S1474-4422(17)30085-6","article-title":"Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Enrico Bertini","year":"2017","journal-title":"The Lancet Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/1474-4465","issn-type":"print"},{"issue":"8","key":"ref19","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1177\/08830738030180080501","article-title":"Role of gabapentin in spinal muscular atrophy: Results of a multicenter, randomized Italian study","volume":"18","author":"Luciano Merlini","year":"2003","journal-title":"Journal of Child Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0883-0738","issn-type":"print"},{"issue":"11","key":"ref20","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1001\/archneur.60.11.1601","article-title":"A Phase 1 Trial of Riluzole in Spinal Muscular Atrophy","volume":"60","author":"Barry S. Russman","year":"2003","journal-title":"Archives of Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0003-9942","issn-type":"print"},{"issue":"1-2","key":"ref21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0022-510X(01)00632-3","article-title":"A placebo-controlled trial of gabapentin in spinal muscular atrophy","volume":"191","author":"R. G. Miller","year":"2001","journal-title":"Journal of the Neurological Sciences","ISSN":"https:\/\/id.crossref.org\/issn\/0022-510X","issn-type":"print"},{"issue":"12a","key":"ref22","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.18553\/jmcp.2018.24.12-a.s3","article-title":"Gene Therapy for Spinal Muscular Atrophy: An Emerging Treatment Option for a Devastating Disease","volume":"24","author":"Vamshi K. Rao","year":"2018","journal-title":"Journal of managed care & specialty pharmacy","ISSN":"https:\/\/id.crossref.org\/issn\/2376-1032","issn-type":"print"},{"issue":"22","key":"ref23","doi-asserted-by":"publisher","first-page":"10067","DOI":"10.1021\/acs.jmedchem.6b00670","article-title":"Small Molecules in Development for the Treatment of Spinal Muscular Atrophy","volume":"59","author":"Alyssa N. Calder","year":"2016","journal-title":"Journal of Medicinal Chemistry","ISSN":"https:\/\/id.crossref.org\/issn\/1520-4804","issn-type":"print"},{"issue":"5","key":"ref24","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/mus.26017","article-title":"CK-2127107 amplifies skeletal muscle response to nerve activation in humans","volume":"57","author":"Jinsy A. Andrews","year":"2018","journal-title":"Muscle and Nerve","ISSN":"https:\/\/id.crossref.org\/issn\/1097-4598","issn-type":"print"},{"key":"ref25","article-title":"An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy - Full Text View - ClinicalTrials.gov","year":"2020"},{"issue":"7","key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-019932","article-title":"Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2-4 (SPACE trial)","volume":"8","author":"Marloes Stam","year":"2018","journal-title":"BMJ Open","ISSN":"https:\/\/id.crossref.org\/issn\/2044-6055","issn-type":"print"},{"issue":"3","key":"ref27","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40265-018-0868-8","article-title":"Overview of Current Drugs and Molecules in Development for Spinal Muscular Atrophy Therapy","volume":"78","author":"Hannah K. Shorrock","year":"2018","journal-title":"Drugs","ISSN":"https:\/\/id.crossref.org\/issn\/1179-1950","issn-type":"print"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"S207","DOI":"10.1016\/j.nmd.2017.06.411","article-title":"Safety and efficacy findings in the first-in-human trial (FIH) of the oral splice modulator branaplam in type 1 spinal muscular atrophy (SMA): interim results","volume":"27","author":"L. Charnas","year":"2017","journal-title":"Neuromuscular Disorders","ISSN":"https:\/\/id.crossref.org\/issn\/0960-8966","issn-type":"print"},{"issue":"18","key":"ref29","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/nejmoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"Jerry R. Mendell","year":"2017","journal-title":"New England Journal of Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"5","key":"ref30","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ana.20473","article-title":"Natural history of denervation in SMA: Relation to age, SMN2 copy number, and function","volume":"57","author":"Kathryn J. Swoboda","year":"2005","journal-title":"Annals of Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0364-5134","issn-type":"print"},{"issue":"2","key":"ref31","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3233\/JND-180304","article-title":"Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy through Newborn Screening","volume":"5","author":"Jacqueline Glascock","year":"2018","journal-title":"Journal of neuromuscular diseases","ISSN":"https:\/\/id.crossref.org\/issn\/2214-3599","issn-type":"print"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1177\/1756285618754459","article-title":"Nusinersen for spinal muscular atrophy","volume":"11","author":"Claudia D. Wurster","year":"2018","journal-title":"Therapeutic Advances in Neurological Disorders","ISSN":"https:\/\/id.crossref.org\/issn\/1756-2864","issn-type":"print"},{"issue":"3","key":"ref33","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1053\/j.semperi.2015.03.006","article-title":"Newborn screening for spinal muscular atrophy: Anticipating an imminent need","volume":"39","author":"Han C. Phan","year":"2015","journal-title":"Seminars in Perinatology","ISSN":"https:\/\/id.crossref.org\/issn\/1558-075X","issn-type":"print"},{"key":"ref34","article-title":"HIGHLIGHTS OF PRESCRIBING INFORMATION FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Dosing Information 2.2 Important Administration Instructions 2.3 Laboratory Testing and Monitoring to Assess Safety 3 DOS","author":"Fda","year":"0"},{"key":"ref35","article-title":"Nusinersen | DrugBank Online","year":"0"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0711-7","article-title":"Nusinersen: First Global Approval","author":"Sheridan M. Hoy","year":"2017","journal-title":"Drugs","ISSN":"https:\/\/id.crossref.org\/issn\/1179-1950","issn-type":"print"},{"issue":"8","key":"ref37","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1002\/jcph.884","article-title":"Population Pharmacokinetics of Nusinersen in the Cerebral Spinal Fluid and Plasma of Pediatric Patients With Spinal Muscular Atrophy Following Intrathecal Administrations","volume":"57","author":"Kenneth T. Luu","year":"2017","journal-title":"Journal of Clinical Pharmacology","ISSN":"https:\/\/id.crossref.org\/issn\/1552-4604","issn-type":"print"},{"issue":"9","key":"ref38","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/psp4.12323","article-title":"A Semi-Mechanistic Population Pharmacokinetic Model of Nusinersen: An Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy","volume":"7","author":"Konstantinos Biliouris","year":"2018","journal-title":"CPT: Pharmacometrics and Systems Pharmacology","ISSN":"https:\/\/id.crossref.org\/issn\/2163-8306","issn-type":"print"},{"issue":"3","key":"ref39","doi-asserted-by":"publisher","first-page":"194","DOI":"10.5863\/1551-6776-24.3.194","article-title":"Nusinersen: A novel antisense oligonucleotide for the treatment of spinal muscular atrophy","volume":"24","author":"Erin E. Neil","year":"2019","journal-title":"Journal of Pediatric Pharmacology and Therapeutics","ISSN":"https:\/\/id.crossref.org\/issn\/2331-348X","issn-type":"print"},{"issue":"10","key":"ref40","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a phase 1 study of nusinersen (ISIS-SMN Rx) in children with spinal muscular atrophy","volume":"86","author":"Claudia A. Chiriboga","year":"2016","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/1526-632X","issn-type":"print"},{"issue":"7","key":"ref41","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1177\/0883073815627882","article-title":"Intrathecal Injections in Children with Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience","volume":"31","author":"Manon Hach\u00e9","year":"2016","journal-title":"Journal of Child Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/1708-8283","issn-type":"print"},{"issue":"21","key":"ref42","doi-asserted-by":"publisher","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","article-title":"Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1\/2 studies","volume":"92","author":"Basil T. Darras","year":"2019","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/1526-632X","issn-type":"print"},{"issue":"1","key":"ref43","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - A literature review","volume":"12","author":"Ingrid E.C. Verhaart","year":"2017","journal-title":"Orphanet Journal of Rare Diseases","ISSN":"https:\/\/id.crossref.org\/issn\/1750-1172","issn-type":"print"},{"issue":"4","key":"ref44","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/mus.26633","article-title":"Nusinersen improves walking distance and reduces fatigue in later-onset spinal muscular atrophy","volume":"60","author":"Jacqueline Montes","year":"2019","journal-title":"Muscle and Nerve","ISSN":"https:\/\/id.crossref.org\/issn\/1097-4598","issn-type":"print"},{"issue":"10063","key":"ref45","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Richard S. Finkel","year":"2016","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/1474-547X","issn-type":"print"},{"issue":"5","key":"ref46","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/jhg.2015.16","article-title":"A new method for SMN1 and hybrid SMN gene analysis in spinal muscular atrophy using long-range PCR followed by sequencing","volume":"60","author":"Yuji Kubo","year":"2015","journal-title":"Journal of Human Genetics","ISSN":"https:\/\/id.crossref.org\/issn\/1435-232X","issn-type":"print"},{"issue":"18","key":"ref47","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/nejmoa1702752","article-title":"Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy","volume":"377","author":"Richard S. Finkel","year":"2017","journal-title":"New England Journal of Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"14","key":"ref48","doi-asserted-by":"publisher","first-page":"E1312","DOI":"10.1212\/WNL.0000000000006281","article-title":"Nusinersen in patients older than 7 months with spinal muscular atrophy type 1","volume":"91","author":"Karolina Aragon-Gawinska","year":"2018","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/1526-632X","issn-type":"print"},{"issue":"7","key":"ref49","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/nejmoa1710504","article-title":"Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy","volume":"378","author":"Eugenio Mercuri","year":"2018","journal-title":"New England Journal of Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"6","key":"ref50","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23061302","article-title":"A half-century history of applications of antisense oligonucleotides in medicine, agriculture and forestry: we should continue the journey","volume":"23","author":"V. Volodymyr Oberemok","year":"2018","journal-title":"Molecules","ISSN":"https:\/\/id.crossref.org\/issn\/1420-3049","issn-type":"print"},{"issue":"1","key":"ref51","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1146\/annurev-med-041217-010829","article-title":"Therapeutic Antisense Oligonucleotides Are Coming of Age","volume":"70","author":"C. Frank Bennett","year":"2019","journal-title":"Annual Review of Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0066-4219","issn-type":"print"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(58)90002-X","article-title":"Descriptive epidemiology of selected neurologic and myopathic disorders with particular reference to a survey in Rochester, Minnesota","author":"Leonard T. Kurland","year":"1958","journal-title":"Journal of Chronic Diseases","ISSN":"https:\/\/id.crossref.org\/issn\/0021-9681","issn-type":"print"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.1320410216","article-title":"Prevalence of type I spinal muscular atrophy in North Dakota","author":"L. Burd","year":"1991","journal-title":"American Journal of Medical Genetics","ISSN":"https:\/\/id.crossref.org\/issn\/0148-7299","issn-type":"print"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0004.1988.tb02854.x","article-title":"Child neuromuscular disease in Southern Norway: Prevalence, age and distribution of diagnosis with special reference to \u201cnon\u2010Duchenne muscular dystrophy\u201d","author":"Svein\u2010Erik \u2010E Tangsrud","year":"1988","journal-title":"Clinical Genetics","ISSN":"https:\/\/id.crossref.org\/issn\/1399-0004","issn-type":"print"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-8966(99)00055-3","article-title":"Neuromuscular disorders in childhood: A descriptive epidemiological study from western Sweden","author":"N. Darin","year":"2000","journal-title":"Neuromuscular Disorders","ISSN":"https:\/\/id.crossref.org\/issn\/0960-8966","issn-type":"print"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2004-0668","article-title":"Spinal muscular atrophy: Survival pattern and functional status","author":"Brian H.Y. Chung","year":"2004","journal-title":"Pediatrics","ISSN":"https:\/\/id.crossref.org\/issn\/0031-4005","issn-type":"print"},{"issue":"11","key":"ref57","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"Darryl C. De Vivo","year":"2019","journal-title":"Neuromuscular Disorders","ISSN":"https:\/\/id.crossref.org\/issn\/1873-2364","issn-type":"print"},{"issue":"1","key":"ref58","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/BPO.0000000000000396","article-title":"Long-term Follow-up of Pulmonary Function and Scoliosis in Patients with Duchenne's Muscular Dystrophy and Spinal Muscular Atrophy","volume":"36","author":"Kenon Chua","year":"2016","journal-title":"Journal of Pediatric Orthopaedics","ISSN":"https:\/\/id.crossref.org\/issn\/1539-2570","issn-type":"print"}],"container-title":["Orthopedic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/orthopedicreviews.openmedicalpublishing.org\/article\/24934-the-antisense-oligonucleotide-nusinersen-for-treatment-of-spinal-muscular-atrophy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T15:03:04Z","timestamp":1739286184000},"score":1,"resource":{"primary":{"URL":"https:\/\/orthopedicreviews.openmedicalpublishing.org\/article\/24934-the-antisense-oligonucleotide-nusinersen-for-treatment-of-spinal-muscular-atrophy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,19]]},"references-count":58,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.52965\/001c.24934","relation":{},"ISSN":["2035-8164"],"issn-type":[{"value":"2035-8164","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,19]]}}}